within Pharmacolibrary.Drugs.ATC.L;

model L01BA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.8,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.105,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Pralatrexate is an antineoplastic agent and antifolate designed to accumulate preferentially in cancer cells. It inhibits dihydrofolate reductase (DHFR), disrupting DNA synthesis. Pralatrexate is primarily used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and is approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with relapsed or refractory peripheral T-cell lymphoma following a 30 mg/m2 dose administered intravenously over 3-5 minutes.</p><h4>References</h4><ol><li>Francine M Foss,Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.,Expert opinion on drug metabolism & toxicology,2011<a href='https://pubmed.ncbi.nlm.nih.gov/21726160/'>https://pubmed.ncbi.nlm.nih.gov/21726160/</a></li><li>Serdar Altınay, Alev Kural, Aykut Özmen, Deniz Tural, Yusuf Tutar,Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind.,Anti-cancer agents in medicinal chemistry,2023<a href='https://pubmed.ncbi.nlm.nih.gov/35692151/'>https://pubmed.ncbi.nlm.nih.gov/35692151/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01BA05;
